News | July 13, 2009

Molecule Programmed to Act as Prostate Cancer "Homing Device"

July 13, 2009 - Purdue University researchers have developed a "homing device" for prostate cancer using by synthesizing a molecule that finds and penetrates prostate cancer cells and using imaging agents and therapeutic drugs that can link to the molecule and be carried with it as cargo.

In the study, led by Philip Low, professor of Biochemistry, Purdue University, radioimaging application for body scans and an optical imaging application used to measure prostate cancer cells in blood samples to detect prostate cancer.

The molecule the team created attaches to prostate-specific membrane antigen, or PSMA, a protein that is found on the membrane of more than 90 percent of all prostate cancers. It also is found on the blood vessels of most solid tumors and could provide a way to cut off the tumor blood supply. There may also be an indication for targeting molecule to be used to attack the vasculature of solid tumors of other types of cancers.

Two papers detailing the work of the Purdue team were published in the June 1 issue of Molecular Pharmaceutics. Endocyte Inc. funded the work.

For more information: www.acs.org

Related Content

Drug Accelerates Blood System's Recovery After Radiation, Chemotherapy

Following radiation, the bone marrow shows nearly complete loss of blood cells in mice (left). Mice treated with the PTP-sigma inhibitor displayed rapid recovery of blood cells (purple, right). Credit: UCLA Broad Stem Cell Research Center/Nature Communications

News | Radiation Therapy | August 16, 2019
A drug developed by UCLA physician-scientists and chemists speeds up the regeneration of mouse and human blood stem...
Mevion and C-RAD Release Integration for Improved Proton Therapy Treatment Quality

Catalyst PT image courtesy of C-RAD

News | Patient Positioning Radiation Therapy | August 15, 2019
Mevion Medical Systems and C-RAD announced the integration between the C-RAD Catalyst PT and the Mevion S250i proton...
First Patient Enrolled in World's Largest Brain Cancer Clinical Trial
News | Radiation Therapy | August 15, 2019
Henry Ford Cancer Institute is first-in-the-world to enroll a glioblastoma patient in the GBM AGILE Trial (Adaptive...
Efficacy of Isoray's Cesium Blu Showcased in Recent Studies
News | Brachytherapy Systems | August 14, 2019
August 14, 2019 — Isoray announced a trio of studies recently reported at scientific meetings and published in medica
MD Anderson to Expand Proton Therapy Center

The MD Anderson Proton Therapy Center expansion is expected to be completed in 2023. Rendering courtesy of Stantec.

News | Proton Therapy | August 08, 2019
The University of Texas MD Anderson Cancer Center unveiled plans to expand its Proton Therapy Center during a...
IBA Signs Contract to Install Proton Therapy Center in Kansas
News | Proton Therapy | August 06, 2019
IBA (Ion Beam Applications S.A.) recently signed a contract and received the first payment for a Proteus One solution...
The top piece of content in July was a video interview explaining how Princess Margaret Cancer Center is using machine learning to create automated treatment plans. This was a hot topic at the American Association of Physicists in Medicine (AAPM) 2019 meeting in July.

The top piece of content in July was a video interview explaining how Princess Margaret Cancer Center is using machine learning to create automated treatment plans. This was a hot topic at the American Association of Physicists in Medicine (AAPM) 2019 meeting in July. 

Feature | August 05, 2019 | Dave Fornell, Editor
August 5, 2019 — Here is the list of the most popular content on the Imaging Technology New (ITN) magazine website fr
Varian Showcases Cancer Care Systems and Software at AAPM 2019
News | Radiation Therapy | August 02, 2019
Varian showcased systems and software from its cancer care portfolio, including the Identify Guidance System, at the...
Laura Dawson, M.D., FASTRO, Chosen as ASTRO President-elect
News | Radiation Oncology | July 31, 2019
The members of the American Society for Radiation Oncology (ASTRO) elected four new officers to ASTRO’s Board of...